5.4 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving RYBELSUS or OZEMPIC tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1), Drug Interactions (7)]
If you are suffering from multiple chronic symptoms or have been diagnosed with a tickborne infection, mast cell activation syndrome, an autoimmune or neuroinflammatory condition, find a physician with expertise in mold illness so you can get properly tested.
Es posible que deba reiniciar el medicamento a una dosis ms baja para evitar problemas estomacales
Global patterns and trends in breast cancer incidence and mortality across 185 countries
2 As an incretin, GLP-1 regulates post-prandial glucose levels
It has been reported as a possible side effect of GLP-1 receptor agonists, particularly semaglutide and tirzepatide